PDS Biotechnology(PDSB) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

New Analyst Forecast: $PDSB Given 'Buy' Rating
Quiver QuantitativeApr 3 06:27 ET
A. G. P. Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $4.5
Moomoo NewsMar 29 02:32 ET · Ratings
Alliance Global Partners Remains a Buy on PDS Biotechnology (PDSB)
TipRanksMar 28 07:36 ET · Ratings
Q4 2024 PDS Biotechnology Corp Earnings Call
Yahoo FinanceMar 28 00:32 ET
PDS Biotechnology Advances Cancer Immunotherapy Trials
TipRanksMar 27 23:58 ET
10-K: FY2024 Annual Report
SECMar 27 16:31 ET · Announcements

Comments

Trytosaveabit

Mar 27 19:34

Improving

$PDS Biotechnology (PDSB.US)$ Full Year 2024 Financial Results
Net loss for the year ended December 31, 2024, was approximately $37.6 million, or $1.03 per basic and diluted share, compared to a net loss of $42.9 million, or $1.39 per basic and diluted share, for the year ended December 31, 2023. The reduced net loss was primarily the result of decreased operating expenses, partially offset by increased net interest expense.
Research and development expenses for the year ended December 3...

Trytosaveabit

Mar 13 20:01

news

$PDS Biotechnology (PDSB.US)$ Reuters
Just
PDS Biotech Announces FDA Clearance of Ind Application for Combination of Versamune® Muc1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Jaguar8

Mar 13 20:01

NEWS

$PDS Biotechnology (PDSB.US)$
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Thursday, 13th March at 8:00 am
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute
Second Versamune® platform candidate targets MUC1-positive solid tumors
U.S. Patent #12,201,685 covering methods of using combinations of the Versamune® platform and various immun...

1